GILD34:BVMF
Gilead Sciences Inc BDR
65,69 BRL
arrow_downward
-0,18%(-0,12) 1 д.
19.10, 10:25:17 ч. Гринуич-3 · BRL
search
Всички символи
| Символ | Цена | Промяна | % промяна |
|---|
insights_autoГенерира се водещата статистика за GILD34…
Отваряне
65,69 BRL
Висока
65,69 BRL
Ниска
65,69 BRL
Пазарна кап.
191,77 млрд.
Ср. обем
319,00
Обем
1,00
Най-висока цена за 52 седм.
67,38 BRL
Най-ниска цена за 52 седм.
51,33 BRL
Акции в обращение
1,24 млрд.
Брой служители
17 хил.
Отваряне
65,69 BRL
Висока
65,69 BRL
Ниска
65,69 BRL
Пазарна кап.
191,77 млрд.
Ср. обем
319,00
Обем
1,00
Най-висока цена за 52 седм.
67,38 BRL
Най-ниска цена за 52 седм.
51,33 BRL
Акции в обращение
1,24 млрд.
Брой служители
17 хил.
Новинарски материали
От източници в мрежата и новинарски партньори
Trefis
·
преди 22 минути
What Has Changed About Owning Gilead Stock?
ad-hoc-news.de
·
преди 1 час
Gilead Sciences stock: BofA lifts target for Gilead Sciences stock to USD 164.00
STAT
·
преди 2 часа
Pharmalittle: We're reading about Roche investments in Germany, a Gilead bowel disease drug, and more
Investing.com
·
преди 3 часа
Gilead to present HIV and antiviral research at IDWeek 2026
Профил
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Всичко за Gilead Sciences Inc BDR
Главен изпълнителен директорДаниел О'дей
Служители17 хил.
Дата на основаване22.06.1987 г.
Централен офисФостър Сити, Калифорния, Съединени щати
Бранш-
Уебсайтgilead.com